Authors
Akihiro Nishiyama, Shigeki Sato, Hiroyuki Sakaguchi, Hiroshi Kotani, Kaname Yamashita, Koushiro Ohtsubo, Shigeki Nanjo, Seiji Yano, Keishi Mizuguchi, Hiroko Ikeda, Makiko Yamaguchi, Tamotsu Ishizuka, Satoko Baba, Kengo Takeuchi, Shinji Takeuchi
Published in
JTO clinical and research reports. Volume 7. Issue 8. Pages 101026. Epub Jun 01, 2026.
Abstract
This study presents the development and characterization of a novel lung adenocarcinoma cell line with kinesin family member 5B rearranged during transfection (KIF5B-RET) fusion, derived from a single patient's pleural effusion.
A pleural effusion sample was collected from a patient with RET fusion-positive NSCLC. The cell line was developed from the pleural effusion, and its characteristics were investigated in vitro and in vivo. Information on lung cancer cell lines with RET fusions was collected through a literature review. The characteristics of the RET fusion-positive cell line developed were then compared with information on RET fusion-positive cell lines identified in the literature.
The newly established PB302 cell line has the following three key characteristics: high sensitivity to selective RET inhibitors, the ability to grow in the central nervous system, and the ability to grow subcutaneously in immunodeficient mice. These features enabled the development of central nervous system disease and subcutaneous tumor models. A comparative analysis revealed that PB302 uniquely possesses these characteristics among RET-positive lung adenocarcinoma cell lines.
This cell line highlights several potentials as a tool for preclinical research and drug development.
PMID:
42568736
Bibliographic data and abstract were imported from PubMed on 08 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0